Amphastar Pharmaceuticals (AMPH) Non Operating Income (2013 - 2026)

Amphastar Pharmaceuticals' Non Operating Income history runs 14 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 44.36% year-over-year to -$3.6 million in Q1 2026; TTM through Mar 2026 was -$13.9 million, a 36.56% increase from a year earlier, with the FY2025 full-year figure at -$16.8 million, down 7.18% from the prior year.
• Non Operating Income grew to -$3.6 million in Q1 2026 per AMPH's latest filing, from -$3.7 million in the prior quarter.
• Across five years, Non Operating Income topped out at $7.4 million in Q1 2022 and bottomed at -$12.6 million in Q4 2023.
• The 5-year median for Non Operating Income is -$3.6 million (2026), against an average of -$3.1 million.
• Across the five-year window, Non Operating Income jumped 242.89% in 2022 and plunged 4699.25% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $3.4 million in 2022, then slumped by 468.58% to -$12.6 million in 2023, then surged by 90.65% to -$1.2 million in 2024, then plunged by 212.35% to -$3.7 million in 2025, then gained by 3.09% to -$3.6 million in 2026.
• Per Business Quant, the three latest AMPH Non Operating Income figures stand at -$3.6 million (Q1 2026), -$3.7 million (Q4 2025), and -$3.8 million (Q3 2025).